ArticleAbdominal radiology (New York)2026
Functional liver imaging score in chronic liver disease: association with hepatocellular function and disease severity markers.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the association of the Functional Liver Imaging Score (FLIS), derived from gadoxetic acid-enhanced MRI (GA-MRI), with clinical and imaging markers of liver function and disease severity in patients with chronic liver disease (CLD), and to determine whether FLIS primarily reflects hepatocellular function or overall disease severity.
methodsNinety-four patients with CLD who underwent GA-MRI between January 2023 and June 2025 were retrospectively analyzed. FLIS, Relative Liver Enhancement (RLE), and Liver-to-Spleen Index (LSI) were calculated from hepatobiliary-phase images. Patients were classified according to disease severity (non-ACLD, cACLD, and dACLD), Child-Pugh class, and FIB-4 score. Associations among FLIS, quantitative imaging parameters, and clinical severity markers were evaluated using correlation and group-comparison analyses.
resultsBoth Child-Pugh class and FIB-4 score were significantly associated with disease severity (p < 0.001). FLIS demonstrated a significant association with Child-Pugh class (p < 0.001), with higher scores observed in patients with better preserved liver function. Among FLIS components, hepatobiliary-phase parenchymal enhancement differed significantly across disease severity groups. FLIS correlated positively with RLE and LSI (both p < 0.001). Effect size analysis showed that FIB-4 and spleen size had stronger associations with disease severity than FLIS.
conclusionFLIS was associated primarily with markers of hepatocellular function, particularly Child-Pugh class, whereas FIB-4 and spleen size showed stronger relationships with overall disease severity. These findings suggest that FLIS may be used as a complementary imaging biomarker of hepatocellular function, but should not replace established clinical indices such as Child-Pugh and FIB-4.
trial registrationNot applicable. This study is a retrospective observational study and did not involve a prospective health care intervention.
Indexed as
Identifiers
42489913What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.